Please login to the form below
Aduro
This page shows the latest Aduro news and features for those working in and with pharma, biotech and healthcare.
Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs
Last year, Lilly announced a $650m partnership with US biotech ImmuNext in the autoimmune disease area, which came just a few months after it launched a $620m partnership with Aduro Biotech
Latest news
-
Bayer signs €250m pact with India’s Curadev for STING drugs
Eli Lilly, for example, paid $12m upfront in a $620 million deal with Aduro Biotech at the end of 2018 for STING inhibitors, focusing on autoimmune diseases. ... There’s still interest in STING agonists, despite disappointing results for
-
AbbVie cures STING fever with Mavupharma acquisition
Shortly afterwards, Aduro reported data for its ADU-S100, which seemed to far a little better than MK-1454 in its phase 1 trial but was still a long way from ... Novartis paid $200m upfront for rights to Aduro’s STING programme in 2015.
-
Dynavax is ‘deal-ready’ after solid ESMO data; analyst
The data from Merck’s study are still maturing, and clinical results from another STING agonist from Novartis/Aduro is due for presentation at the SITC conference in Washington DC next
-
J&J moves quickly ahead with trials of myeloma CAR-T
Earlier this month it bought oncolytic virus player Benevir Biopharm for $140m upfront and up to $900m in milestones, and also has a collaboration with Aduro for cancer vaccine ADU-214
-
Aduro pancreatic cancer vaccine trial disappoints
Immunotherapy combination fails to improve overall survival over existing treatments. Aduro's combination immunotherapy regimen has failed a phase III trial in pancreatic cancer, the second cancer vaccine to do so ... The immunotherapy combines CRS-207 -
More from news
Approximately 3 fully matching, plus 9 partially matching documents found.
Latest Intelligence
-
Cancer immunotherapy: What's on the horizon?
Among the plethora in the pipeline, Aurigene and BMS are looking at PD-1 inhibitors that can be dosed orally, Novartis, iTeos and Aduro are developing STING agonists that can ... marked more by failures than successes, with a string of candidates
-
Medius Deal Watch table for March 2015
825. Aduro / Novartis. Licence and collaboration. Preclinical cancer immunotherapies targeting the STING (Stimulator of Interferon Genes) pathway.
-
Pharma deals in March 2015
One such example is Novartis which has CAR-T and checkpoint inhibitor programmes and has now added Aduro's STING (Stimulator of Interferon Genes) technology as an additional string to its ... bow. Aduro has a number of preclinical small molecule cyclic
-
Deal Watch table for October 2014
1, 000. Aduro BioTech/J&J. Expansion of collaboration. Lung cancer immunotherapies including ADU 214.
-
Pharma deals during October 2014
on Aduro's novel LADD [live-attenuated double-deleted Listeria monocytogenes strains that have been engineered to induce an innate immune response] immunotherapy platform. ... Now with a headline of $847m, Aduro receives an upfront of $30m with $817m in
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Subscribe to our email news alerts
- Medscape Education’s Large Presence at IDWeek 2023
- WHO recommends second malaria vaccine for children
- Sanofi enters agreement with Janssen to develop E. coli vaccine candidate
- NFID and CDC urge US adults to get vaccinated against flu and COVID-19
- Man vs microbe: the fight against antimicrobial resistance
- Dollo's law
No results were found
PMHub
Evoke Mind+Matter
We are Evoke Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for...
Latest intelligence
- Man vs microbe: the fight against antimicrobial resistance
- How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics...
- Is trust the key factor in digital HCP engagement? New whitepaper from Graphite Digital
- Based on research with HCPs in the UK, USA and France, Graphite Digital’s latest whitepaper sheds light on HCP perceptions of pharma-owned digital channels, and what organisations should be prioritising...
- HOW TO TRANSFORM YOUR HEALTHCARE BRAND MARKETING FROM MULTI-CHANNEL TO OMNICHANNEL
- In a previous blog, we outlined the role of omnichannel in healthcare and the importance of personalised communications with the suggestion of using modular content to support an omnichannel approach....
